亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

医学 内科学 化疗 肿瘤科 免疫疗法 随机对照试验 胰腺癌 临床试验 癌症 临床研究阶段 外科 梅德林 随机化 吉西他滨 胰腺疾病
作者
Daniel Brock Hewitt,Nicholas Nissen,Hassan Hatoum,Benjamin Musher,John Seng,Andrew L. Coveler,Raed Al-Rajabi,Charles J. Yeo,Benjamin Leiby,Joshua Banks,Lodovico Balducci,Gina Vaccaro,Noelle LoConte,Thomas J. George,Warren Brenner,Emad Elquza,Nicholas Vahanian,Gabriela Rossi,Eugene Kennedy,Charles Link
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
卷期号:275 (1): 45-53 被引量:89
标识
DOI:10.1097/sla.0000000000004669
摘要

OBJECTIVES: To compare the efficacy and safety of algenpantucel-L [HyperAcute-Pancreas algenpantucel-L (HAPa); IND# 12311] immunotherapy combined with standard of care (SOC) chemotherapy and chemoradiation to SOC chemotherapy and chemoradiation therapy alone in patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA: To date, immunotherapy has not been shown to benefit patients with borderline resectable or locally advanced unresectable PDAC. HAPa is a cancer vaccine consisting of allogeneic pancreatic cancer cells engineered to express the murine α(1,3)GT gene. METHODS: A multicenter, phase 3, open label, randomized (1:1) trial of patients with borderline resectable or locally advanced unresectable PDAC. Patients received neoadjuvant SOC chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) followed by chemoradiation (standard group) or the same standard neoadjuvant regimen combined with HAPa immunotherapy (experimental group). The primary outcome was overall survival. RESULTS: Between May 2013 and December 2015, 303 patients were randomized from 32 sites. Median (interquartile range) overall survival was 14.9 (12.2-17.8) months in the standard group (N = 158) and 14.3 (12.6-16.3) months in the experimental group (N = 145) [hazard ratio (HR) 1.02, 95% confidence intervals 0.66-1.58; P = 0.98]. Median progression-free survival was 13.4 months in the standard group and 12.4 months in the experimental group (HR 1.33, 95% confidence intervals 0.72-1.78; P = 0.59). Grade 3 or higher adverse events occurred in 105 of 140 patients (75%) in the standard group and in 115 of 142 patients (81%) in the experimental group (P > 0.05). CONCLUSIONS: Algenpantucel-L immunotherapy did not improve survival in patients with borderline resectable or locally advanced unresectable PDAC receiving SOC neoadjuvant chemotherapy and chemoradiation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01836432.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐应助刻苦的面包采纳,获得10
3秒前
凡舍完成签到 ,获得积分10
6秒前
7秒前
7秒前
9秒前
9秒前
ppx完成签到,获得积分10
9秒前
12秒前
13秒前
xin发布了新的文献求助10
15秒前
今后应助科研通管家采纳,获得10
17秒前
彭于晏应助科研通管家采纳,获得10
18秒前
Copyright应助科研通管家采纳,获得10
18秒前
CodeCraft应助科研通管家采纳,获得10
18秒前
18秒前
wanci应助科研通管家采纳,获得10
18秒前
Bin_Liu完成签到,获得积分20
23秒前
隐形曼青应助满意的月亮采纳,获得10
24秒前
msn00完成签到 ,获得积分10
27秒前
科研通AI6.3应助嗯哼哈哈采纳,获得10
27秒前
29秒前
汉堡包应助楽le采纳,获得10
29秒前
32秒前
35秒前
Allez完成签到,获得积分10
37秒前
40秒前
木子完成签到,获得积分10
41秒前
48秒前
呆萌魏完成签到,获得积分10
50秒前
一只可怜的科研狗完成签到,获得积分10
51秒前
嗯哼哈哈发布了新的文献求助10
53秒前
XX发布了新的文献求助10
53秒前
CodeCraft应助adgnmygn采纳,获得10
55秒前
56秒前
59秒前
完美世界应助故事的角色采纳,获得10
1分钟前
楽le发布了新的文献求助10
1分钟前
Hello应助ecnu搬砖人采纳,获得10
1分钟前
ly发布了新的文献求助30
1分钟前
1分钟前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Molecular Mechanisms of Photosynthesis, 4th Edition 1000
Organic Reactions, Volume 116 1000
Current concepts in cutaneous toxicity : proceedings of the Fourth Conference on Cutaneous Toxicity, Washington, D.C., May 9-11, 1979 1000
The recovery-stress questionnaires : user manual 800
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7257434
求助须知:如何正确求助?哪些是违规求助? 8879428
关于积分的说明 18756898
捐赠科研通 6937882
什么是DOI,文献DOI怎么找? 3201074
关于科研通互助平台的介绍 2375192
邀请新用户注册赠送积分活动 2176930